Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 26

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 26
---
 warrants and warrants sold in this offering were to be exercised, we would receive additional net proceeds of approximately $10.6 million. We cannot predict when or if these pre-funded warrants and warrants will be exercised. It is possible that the warrants may expire without being exercised and the pre-funded warrants may never be exercised. We intend to use the net proceeds of this offering for research and development activities, the expansion of our pipeline of potential drug candidates, and working capital and general corporate purposes. The amounts and timing of our use of the net proceeds will vary depending on a number of factors, including the amount of cash generated or used by our operations, and the rate of growth, if any, of our business. As a result, we will retain broad discretion in the allocation of the net proceeds of this offering. Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. S - 13 DESCRIPTION OF SECURITIES WE ARE OFFERING The material terms and provisions of our ADSs and ordinary shares are described under the headings “Description of American Depositary Shares” and “Description of Ordinary Shares,” respectively, in this prospectus supplement and the accompanying prospectus. Our ADSs are listed on Nasdaq under the symbol “BLRX.” Our ordinary shares trade on the TASE under the symbol “BLRX.” The depositary for the ADSs representing our ordinary shares is The Bank of New York Mellon. Its address is 240 Greenwich Street, New York, New York 10286 and its telephone number is (212) 495-1784. Warrants The following is a summary of the material terms and provisions of the warrants that are being offered hereby. This summary is subject to and qualified in its entirety by the form of warrant, which has been provided to the investors in this offering and will be filed with the SEC as an exhibit to a Report on Form 6-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the warrants. Duration and Exercise Price The warrants offered hereby will have an exercise price of $0.20 per ADS. The warrants will be immediately exercisable and may be exercised until the fifth anniversary of the issuance date. The exercise price and numbers of ADSs issuable upon exercise are